Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $10.00 price target on AbCellera Biologics (NASDAQ: ABCL).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments